GVHD | Oncology Learning Network

GVHD Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Featured

Vedolizumab Tolerable for Prevention of GVHD in Patients Undergoing Allo-HSCT

Study findings showed that vedolizumab 300 mg was tolerable and led to low incidence of overall and lower-intestinal aGVHD in patients who undergo allo-HSCT.

New Therapeutic Target for GVHD Could Make Bone Marrow Transplant Safer

Xue-Zhong Yu, MD, MS, MBA, discusses Sirtuin-1 as a possible therapeutic target for the control of GVHD.

Ruxolitinib Active, Well-Tolerated in Patients With Steroid-Refractory Acute GVHD

In a phase 2 clinical trial, ruxolitinib was well-tolerated and led to responses in >50% of patients with steroid-refractory acute GVHD.

Improved Efficacy Outcomes With Ruxolitinib for GVHD After Allogeneic Transplantation

Ruxolitinib significantly improved efficacy outcomes over common therapy options for patients with glucocorticoid-refractory acute GVHD after allogeneic stem cell transplantation.

Pediatric Patients With Acute Leukemia May Benefit From Reduced GVHD Prophylaxis

Oncologists may be able to reduce GVHD preventative measures for pediatric patients with acute leukemia post-HSCT.